Adaptimmune raises $104 mln to develop immune-system cancer drugs
September 24, 2014 at 19:01 PM EDT
LONDON, Sept 25 (Reuters) - British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells.
